Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the AI stocks that will go to the moon. On February 18, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) came under pressure after regulatory ...
Investing.com -- Recursion Pharmaceuticals (NASDAQ:RXRX) stock tumbled 12% Wednesday morning after regulatory filings revealed that NVIDIA (NASDAQ:NVDA) had completely divested its stake in the ...
MiniMax shares surged after revenue beat expectations in its first set of results following its listing. Shares of the Chinese artificial-intelligence company rose 18% to 884.00 Hong Kong dollars, or ...
Anthropic dropped a bombshell on the artificial intelligence industry Monday, publicly accusing three prominent Chinese AI laboratories — DeepSeek, Moonshot AI, and MiniMax — of orchestrating ...
United States artificial intelligence firm Anthropic is accusing three prominent Chinese AI labs of illegally extracting capabilities from its Claude model to advance their own, claiming it raises ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results